Neuropsychological profile of Alzheimer’s disease based on amyloid biomarker findings results from a South American cohort
- 30 April 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Applied Neuropsychology: Adult
- Vol. 29 (3), 345-350
- https://doi.org/10.1080/23279095.2020.1756816
Abstract
Objective: Increased life expectancy and exponential growth of adults suffering from Alzheimer’s disease (AD) worldwide, has led to biomarkers incorporation for diagnosis in early stages. Use of neuropsychological testing remains limited. This study aimed to identify which neuropsychological tests best indicated underlying AD pathophysiology. Methods: One hundred and forty-one patients with MCI (Mild Cognitive Impairment) were studied. A neuropsychological test battery based on the Uniform Data Set (UDS) from the Alzheimer’s Disease Centers program of the National Institute on Aging (NIA) was performed and amyloid markers recorded; according to presence or absence of amyloid identified by positive PIB-PET findings, or low CSF Aβ42 levels, patients were separated into MCI amyloid–(n:58) and MCI amyloid + (n = 83) cases. Results: Statistical differences were found in all memory tests between groups. Delayed recall score at thirty minutes on the Rey Auditory Verbal Learning Test (AVLT) was the best predictor of amyloid pathology presence (AUC 0.68), followed by AVLT total learning (AUC 0.66) and AVLT Recognition (AUC 0.59) scores, providing useful cut off values in the clinical setting. Conclusions: Use of neuropsychological testing, specifically AVLT scores with cutoff values, contributed to the correct diagnosis of MCI due to AD in this SouthAmerican cohort.Keywords
This publication has 33 references indexed in Scilit:
- Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjectsNeuroImage: Clinical, 2014
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Differential Memory Test Sensitivity for Diagnosing Amnestic Mild Cognitive Impairment and Predicting Conversion to Alzheimer's DiseaseAging, Neuropsychology, and Cognition, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- The Alzheimer's Disease Centers' Uniform Data Set (UDS)Alzheimer Disease & Associated Disorders, 2009
- Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's diseaseBrain, 2009
- Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjectsBrain, 2008
- Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's DiseaseBiological Psychiatry, 2008
- The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's diseaseNeurology, 1989
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982